Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.9K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.9K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

1.6K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.6K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.9K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

4.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.8K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

1.7K
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1.7K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

632
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
632

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical characteristics, management and outcomes of enterococcal infective endocarditis: an ancillary study from the ESC-EORP EURO-ENDO registry.

European heart journal. Quality of care & clinical outcomes·2025
Same author

Diet and Clinical Outcomes in a Heart Failure Population.

JACC. Heart failure·2025
Same author

Rationale, objectives, and design of the HEart failuRe ObsErvational Study of the Polish Cardiac Society (HEROES).

Kardiologia polska·2025
Same author

Seattle proportional risk model in GISSI-HF: Estimated benefit of ICD in patients with EF less than 50.

American heart journal·2024
Same author

Pulmonary Congestion and Left Ventricular Dysfunction After Myocardial Infarction: Insights From the PARADISE-MI Trial.

Circulation·2024
Same author

The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial.

Circulation·2022

Related Experiment Video

Updated: May 5, 2026

A Murine Model of Hemodialysis Access-Related Hand Dysfunction
08:39

A Murine Model of Hemodialysis Access-Related Hand Dysfunction

Published on: May 31, 2022

1.8K

Impact of renal dysfunction on the Seattle Heart Failure Model.

Kairav P Vakil1, Todd Dardas2, Sunil Dhar1

  • 1Division of Cardiology, University of Minnesota, Minneapolis, Minnesota.

The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation
|December 10, 2013
PubMed
Summary

Renal dysfunction predicts heart failure mortality, especially in lower-risk patients. Adding creatinine to the Seattle Heart Failure Model offers minimal improvement in predicting patient outcomes.

Keywords:
Seattle Heart Failure Modelchronic kidney diseaseheart failurerisk prediction

More Related Videos

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

20.5K
A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats
07:31

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats

Published on: December 2, 2016

9.8K

Related Experiment Videos

Last Updated: May 5, 2026

A Murine Model of Hemodialysis Access-Related Hand Dysfunction
08:39

A Murine Model of Hemodialysis Access-Related Hand Dysfunction

Published on: May 31, 2022

1.8K
A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

20.5K
A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats
07:31

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats

Published on: December 2, 2016

9.8K

Area of Science:

  • Cardiology
  • Nephrology
  • Medical Statistics

Background:

  • Renal dysfunction (RD) is a significant predictor of mortality in heart failure (HF) patients.
  • The impact of RD on the predictive accuracy of the Seattle Heart Failure Model (SHFM) remains unclear.

Purpose of the Study:

  • To evaluate the independent predictive value of serum creatinine (SCr) and creatinine clearance (CrCl) for mortality in HF patients.
  • To assess the incremental benefit of adding RD markers to the SHFM for risk prediction.

Main Methods:

  • Analysis of SCr and CrCl in 7,146 patients from SHFM derivation and validation cohorts.
  • Multivariable Cox proportional hazards models and ROC curve analysis were used to assess prediction.
  • Patients were stratified by SHFM risk categories.

Main Results:

  • Both SCr and CrCl independently predicted mortality in HF patients.
  • RD markers provided additional prognostic information primarily in lower-risk individuals.
  • Adding SCr or CrCl to the SHFM resulted in minimal improvement in 1- and 2-year event prediction discrimination.

Conclusions:

  • Renal dysfunction independently predicts mortality in heart failure patients, particularly those at lower risk.
  • Incorporating SCr or CrCl into the SHFM offers only a slight enhancement in overall predictive discrimination.